ASSOCIATION BETWEEN SERUM LEVELS OF ADIPOKINES IN PATIENTS WITH PROSTATE CANCER

Adipokines were proved to be the most important mediators involved in the development and progression of several types of obesity-associated cancers. This study aims to demonstrate the relationship between adipokines and prostate cancer to evaluate the possibility of using adipokines as an early marker for diagnosis of PC and monitoring its development and progression.

The study was conducted with a total of 82 men aged between 45 years and 76 years. The study is divided into two groups: group 1 prostate cancer (n=42) and group 2 healthy control subjects (n=40). The prostate cancer group divided into 3 subgroups according to their Gleason's grading, group 1 of low level (10) group 2 of moderate level (14) and group 3 of high level (18).

Prostate cancer patients had significantly lower levels of adiponectin (2.87±0.73 ng/mL; P<0.001) than did controls (9.9±1.25 ng/mL). the level of Resistin was a significantly high in prostate patient group than control group (14.65±3.43 ng/mL and 10.63±1.37 ng/mL), respectively, when compared to controls (11.6±1.79 ng/mL), the visfatin level in patients with prostate cancer was significantly greater (20.5±4.54 ng/mL) regarding the level of chemerin there was a significantly increased in patients' group (979±149.6 pg/mL) than control group (204±41pg/mL) also, the present study confirm that there is a significant correlation between the parameters serum level and PSA as well as BMI.

Our findings showed that the levels of adiponectin were strongly reduced in the patients' group. other parameters were significantly higher compared with control group. Also, there are strong correlation between the levels of chemerin/ adiponectin ratio and the severity of the disease, suggesting the importance of this ratio to monitoring response to the treatment of prostate cancer, predicating the possibility of using these findings as PCa markers in early stage of disease.